Characteristics of the suppressive effect of nicardipine on peroxisome induction in rat liver.
In vivo administration of nicardipine, a known calcium antagonist, suppressed the clofibrate-evoked induction of activities of peroxisomal enzymes, such as catalase, the peroxisomal fatty acyl-CoA oxidizing system, carnitine acetyltransferase and mitochondrial carnitine palmitoyltransferase in rat liver. On a time-course study, the suppression of induction in the activities of the peroxisomal fatty acyl-CoA oxidizing system and carnitine acetyltransferase was found at 5 days after the treatment, whereas the induction by clofibrate was already observed at 1 day after the treatment, suggesting that in the process of peroxisome induction by clofibrate there might be two steps, i.e., a triggering step and an enhancing step, and nicardipine might act as suppressor for the later step. The precursor-incorporation studies with [3H]leucine showed that the rate of the synthesis of the peroxisomal bifunctional enzyme was increased by 4.2-fold after clofibrate-treatment, whereas nicardipine suppressed this enhancement to only 2.2-fold of the control. The rate of degradation of this enzyme was not affected by any treatment. These results show that nicardipine affects the regulation mechanism of the biosynthesis of this enzyme. Nicardipine showed hardly any suppressive-effect on the hepatic peroxisomal enzyme induction observed in high-fat diet fed rat. Furthermore, the suppression of clofibrate-evoked induction of peroxisomal enzymes was observed also in mice. These interesting findings suggest that there is a difference in the mechanism of peroxisome proliferation and/or the induction of peroxisomal enzymes between clofibrate and physiological conditions, such as high-fat diet feeding. The suppression of drug-induced peroxisome proliferation by calcium antagonists may help in dissecting the causal relationship between the multiple effects mediated by peroxisomal proliferators.
Itoga
H
H
Department of Clinical Biochemistry, Tokyo College of Pharmacy, Hachioji, Japan.
Tamura
H
H
Watanabe
T
T
Suga
T
T
D015094:3-Hydroxyacyl CoA Dehydrogenases / Q000096:biosynthesis*; D000818:Animals; D002994:Clofibrate / Q000494:pharmacology; D004041:Dietary Fats / Q000008:administration & dosage; D004591:Electrophoresis, Polyacrylamide Gel; D004746:Enoyl-CoA Hydratase / Q000096:biosynthesis*; D004790:Enzyme Induction; D006836:Hydro-Lyases / Q000096:biosynthesis*; D008099:Liver / Q000187:drug effects; D008297:Male; D008830:Microbodies / Q000187:drug effects* / Q000201:enzymology; D008930:Mitochondria, Liver / Q000187:drug effects / Q000201:enzymology; D009529:Nicardipine / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains
D004041:Dietary Fats; D009529:Nicardipine; D015094:3-Hydroxyacyl CoA Dehydrogenases; D006836:Hydro-Lyases; D004746:Enoyl-CoA Hydratase; D002994:Clofibrate